Contribution: Industrial Research Assistance Program – Contributions to Firms
Syng Pharmaceuticals Inc.
$0.00
Development of first in vitro diagnostic kit for Endometriosis
FY 2017-18 · 2017-10-02
Summary
SYNG Pharma is developing first, in vitro test for endometriosis. This project will validate analytical methods for antigen antibody detection using different matrices, development of lateral flow device and generate new IP for detection of a new biomarker for endometriosis.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Kingston|Kingston, Ontario, Canada
Recipient Type
For-profit organization
Business Number
842703845
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
As published
Additional Information
The end date of this agreement has been modified by 91 days.
Additional Information (French)
La date de fin du présent accord a été changé (91 jours)
Agreement End Date
2018-06-30
Agreement Number
893052
Agreement Start Date
2017-10-02
Agreement Title
Development of first in vitro diagnostic kit for Endometriosis
Agreement Title (French)
Développement d'une première trousse de diagnostic in vitro pour l'endométriose
Agreement Type
Contribution
Agreement Value
$0.00
Amendment Date
2018-04-03
Amendment Number
1
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
SYNG Pharma is developing first, in vitro test for endometriosis. This project will validate analytical methods for antigen antibody detection using different matrices, development of lateral flow device and generate new IP for detection of a new biomarker for endometriosis.
Description (French)
SYNG Pharma est en train de développer les premiers essais in vitro pour l'endométriose. Ce projet permettra de valider les méthodes d’analyse pour la détection des anticorps d'antigène en utilisant différentes matrices, le développement de dispositif de circulation latérale et générer de nouvelles IP pour la détection d'un nouveau biomarqueur pour l'endométriose.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Kingston and the Islands
Federal Riding (French)
Kingston et les Îles
Federal Riding Number
35044
NAICS Code
54171
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
842703845
Recipient City
Kingston|Kingston
Recipient Country
CA
Recipient Legal Name
Syng Pharmaceuticals Inc.
Recipient Postal Code
K7P 2A4
Recipient Province or Territory
ON
Recipient Type
F
Reference Number
172-2018-2019-Q1-893052
